NDT Advance Access originally published online on April 7, 2006
Nephrology Dialysis Transplantation 2006 21(7):1999-2004; doi:10.1093/ndt/gfl114
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Case Report
Successful treatment of calciphylaxis with cinacalcet—an alternative to parathyroidectomy?
The John Stevenson Lynch Renal Unit, NHS Ayrshire & Arran, Crosshouse Hospital, Kilmarnock, Scotland
Correspondence and offprint requests to: Dr Nestor Velasco, Consultant Nephrologist, The John Stevenson Lynch Renal Unit, Crosshouse Hospital, Kilmarnock KA2 0BE, Scotland. Email: nestor.velasco@aaaht.scot.nhs.uk
Keywords: calciphylaxis; calcium-sensing receptors; cinacalcet; parathyroid hormone; renal replacement therapy; secondary hyperparathyroidism
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
Calciphylaxis is a rare but serious complication of end-stage renal failure, which has a high mortality due to widespread vascular calcification and refractory infections [1,2]. Parathyroidectomy has been advocated as one of the few treatments that may reverse this condition [3], although this has not been universally accepted and is not always successful [4]. The newly developed calcimimetic, cinacalcet (marketed as Mimpara® in the EU, and as Sensipar® in the USA by Amgen Inc., Thousand Oaks, CA, USA) produces rapid biochemical control of secondary hyperparathyroidism [5,6], and thus may represent an alternative treatment for patients with calciphylaxis.
|
Case report |
|---|
A 45-year-old man with end-stage renal failure due to autosomal dominant polycystic kidney disease started treatment with peritoneal dialysis in 2000. He had hypertension and asthma, but no other comorbidities and was a non-smoker. He transferred to haemodialysis in 2002, after
|
Discussion |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Khalpey, M. A. Nehs, A. W. ElBardissi, M. Semel, and S. G. Tullius The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism NDT Plus, September 8, 2009; (2009) sfp120v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Lopez, F. J. Mendoza, F. Guerrero, Y. Almaden, C. Henley, E. Aguilera-Tejero, and M. Rodriguez The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1376 - F1385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Raymond and L. D. Wazny Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis Am. J. Health Syst. Pharm., August 1, 2008; 65(15): 1419 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mandelbrot, P. W. Santos, R. K. Burt, Y. Oyama, G. A. Block, S. N. Ahya, R. M. Rosa, and A. E. Traynor Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2679 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Robinson, J. J. Augustine, and N. J. Korman Sodium Thiosulfate as First-Line Treatment for Calciphylaxis Reply Arch Dermatol, October 1, 2007; 143(10): 1338 - 1338. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bazari, M. R. Jaff, M. Mannstadt, and S. Yan Case 7-2007 -- A 59-Year-Old Woman with Diabetic Renal Disease and Nonhealing Skin Ulcers N. Engl. J. Med., March 8, 2007; 356(10): 1049 - 1057. [Full Text] [PDF]
|
|
|
|
 |
|
 A New Medical Treatment for Calciphylaxis? Journal Watch Dermatology, September 15, 2006; 2006(915): 2 - 2. [Full Text]
|
|